PT3337478T - Combinação de fármacos compreendendo irinotecano lipossómico, oxaliplatina, 5-fluorouracilo e leucovorina para o tratamento do cancro do pâncreas metastático - Google Patents

Combinação de fármacos compreendendo irinotecano lipossómico, oxaliplatina, 5-fluorouracilo e leucovorina para o tratamento do cancro do pâncreas metastático

Info

Publication number
PT3337478T
PT3337478T PT167583376T PT16758337T PT3337478T PT 3337478 T PT3337478 T PT 3337478T PT 167583376 T PT167583376 T PT 167583376T PT 16758337 T PT16758337 T PT 16758337T PT 3337478 T PT3337478 T PT 3337478T
Authority
PT
Portugal
Prior art keywords
oxaliplatin
methods
pancreatic cancer
combination therapies
metastatic pancreatic
Prior art date
Application number
PT167583376T
Other languages
English (en)
Original Assignee
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58100730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3337478(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ipsen Biopharm Ltd filed Critical Ipsen Biopharm Ltd
Publication of PT3337478T publication Critical patent/PT3337478T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PT167583376T 2015-08-21 2016-08-19 Combinação de fármacos compreendendo irinotecano lipossómico, oxaliplatina, 5-fluorouracilo e leucovorina para o tratamento do cancro do pâncreas metastático PT3337478T (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562208209P 2015-08-21 2015-08-21
US201562216736P 2015-09-10 2015-09-10
US201562273244P 2015-12-30 2015-12-30
US201662281473P 2016-01-21 2016-01-21
US201662302341P 2016-03-02 2016-03-02
US201662323245P 2016-04-15 2016-04-15
US201662343313P 2016-05-31 2016-05-31

Publications (1)

Publication Number Publication Date
PT3337478T true PT3337478T (pt) 2020-10-19

Family

ID=58100730

Family Applications (1)

Application Number Title Priority Date Filing Date
PT167583376T PT3337478T (pt) 2015-08-21 2016-08-19 Combinação de fármacos compreendendo irinotecano lipossómico, oxaliplatina, 5-fluorouracilo e leucovorina para o tratamento do cancro do pâncreas metastático

Country Status (18)

Country Link
US (3) US20170049775A1 (pt)
EP (2) EP3791876A1 (pt)
JP (3) JP2018528185A (pt)
KR (1) KR20180039087A (pt)
CN (1) CN108495629A (pt)
AU (1) AU2016310476B8 (pt)
BR (1) BR112018002941B1 (pt)
CA (1) CA2993451A1 (pt)
ES (1) ES2826826T3 (pt)
HK (2) HK1257220A1 (pt)
IL (1) IL257149A (pt)
MX (1) MX2018001802A (pt)
PT (1) PT3337478T (pt)
RU (1) RU2747124C2 (pt)
SG (1) SG10201913077QA (pt)
SI (1) SI3337478T1 (pt)
TW (4) TWI778942B (pt)
WO (1) WO2017034957A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
EP3229802A1 (en) * 2014-12-09 2017-10-18 Ipsen Biopharm Ltd. Treatment of breast cancer with liposomal irinotecan
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
CA2992789A1 (en) 2015-08-20 2017-02-23 Ipsen Biopharm Ltd. Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
EP3791876A1 (en) 2015-08-21 2021-03-17 Ipsen Biopharm Ltd. Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
MX2018004328A (es) 2015-10-16 2018-08-01 Ipsen Biopharm Ltd Composiciones farmaceuticas estabilizantes de camptotecina.
SG11201903615WA (en) 2016-11-02 2019-05-30 Ipsen Biopharm Ltd Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
US20220010016A1 (en) * 2018-10-17 2022-01-13 Biolinerx Ltd. Treatment of metastatic pancreatic adenocarcinoma
WO2020148745A1 (en) * 2019-01-17 2020-07-23 Biolinerx Ltd. Specific combination therapy for treatment of pancreatic cancer
WO2020148744A1 (en) * 2019-01-17 2020-07-23 Biolinerx Ltd. Combination therapy for treatment of pancreatic cancer
EP3911299A1 (en) * 2019-02-22 2021-11-24 Novocure GmbH Treating gastric cancer using ttfields combined with xelox or folfox
WO2021072407A1 (en) * 2019-10-10 2021-04-15 The University Of North Carolina At Chapel Hill Delivery system complexes comprising a precipitate of an active agent and methods of use
EP4355366A1 (en) * 2021-06-16 2024-04-24 Fusion Pharmaceuticals Inc. Combination comprising a neurotensin receptor binding compound and napoli
EP4355317A1 (en) * 2021-06-16 2024-04-24 Fusion Pharmaceuticals Inc. Combination comprising a neurotensin receptor binding compound and napox

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
JPH0720857B2 (ja) 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5538954A (en) 1994-06-24 1996-07-23 A/S Dumex (Dumex Ltd.) Salts of tetracyclines
US5783568A (en) 1994-06-10 1998-07-21 Sugen, Inc. Methods for treating cancer and other cell proliferative diseases
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
DE19605024A1 (de) 1996-01-31 1997-08-07 Schering Ag Neue selektive Taxane, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
WO1998017256A1 (en) 1996-10-22 1998-04-30 Dmitri Kirpotin Compound-loaded liposomes and methods for their preparation
US6210707B1 (en) 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
US6787132B1 (en) 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
US6726925B1 (en) 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
DK1121102T3 (da) 1998-09-16 2003-08-11 Alza Corp Liposomindesluttede topoisomeraseinhibitorer
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
WO2000066125A1 (en) 1999-04-29 2000-11-09 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
WO2001056548A2 (en) 2000-02-04 2001-08-09 Lipoxen Technologies Limited Liposomes composition produced by a dehydration-rehydration process
US6545010B2 (en) 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
CA2408710C (en) 2000-05-15 2010-01-26 Celgene Corp. Compositions and methods for the treatment of colorectal cancer
ATE309787T1 (de) 2000-06-30 2005-12-15 Inex Pharmaceuticals Corp Verbesserte liposomale camptothecine und deren verwendungen
TWI283575B (en) 2000-10-31 2007-07-11 Eisai Co Ltd Medicinal compositions for concomitant use as anticancer agent
CA2442261A1 (en) 2001-03-26 2002-10-03 Alza Corporation Liposome composition for improved intracellular delivery of a therapeutic agent
US7219016B2 (en) 2001-04-20 2007-05-15 Yale University Systems and methods for automated analysis of cells and tissues
WO2003030864A1 (en) 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
JP2005505526A (ja) 2001-07-23 2005-02-24 エピダウロス・バイオテクノロジー・アクチェンゲゼルシャフト Ｕｇｔ１ａ１に基づいたがんの改善治療の手段及び方法
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
CA2752143C (en) 2002-05-15 2014-09-23 Sutter West Bay Hospitals Delivery of nucleic acid-like compounds
WO2003101474A1 (en) 2002-05-31 2003-12-11 Transmolecular, Inc. Combination chemotherapy with chlorotoxin
AU2003296897A1 (en) 2002-08-20 2004-05-04 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
KR20180132969A (ko) 2003-05-30 2018-12-12 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
KR101376895B1 (ko) 2004-05-03 2014-03-25 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
AP2255A (en) 2004-06-01 2011-07-21 Yakult Honsha Kk Irinotecan preparation.
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
US20100189771A1 (en) 2005-10-25 2010-07-29 Lawrence Mayer Fixed ratio drug combination treatments for solid tumors
US20090148506A1 (en) 2005-12-22 2009-06-11 Awa Dicko Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof
US20070265324A1 (en) 2006-01-17 2007-11-15 Wolfgang Wernet Combination Therapy with Parp Inhibitors
US20070219268A1 (en) 2006-03-16 2007-09-20 Bionumerik Pharmaceuticals, Inc. Anti-cancer activity augmentation compounds and formulations and methods of use thereof
EP3248617A3 (en) 2007-02-16 2018-02-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
US20120003160A1 (en) 2007-06-29 2012-01-05 Amag Pharmaceuticals, Inc. Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session
WO2009097011A1 (en) 2007-08-17 2009-08-06 Celator Pharmaceuticals, Inc. Improved platinum drug formulations
JP2010540498A (ja) 2007-09-28 2010-12-24 ウニヴェルズィテーツシュピタール バーゼル 癌の治療のための免疫リポソーム
CN101918003A (zh) 2007-11-12 2010-12-15 彼帕科学公司 单独使用parp抑制剂或与抗肿瘤剂组合治疗子宫癌和卵巢癌
AU2008333786A1 (en) 2007-12-07 2009-06-11 Bipar Sciences, Inc. Treatment of cancer with combinations of topoisomerase inhibitors and PARP inhibitors
JP2011515478A (ja) 2008-03-25 2011-05-19 シェーリング コーポレイション 結腸直腸がんを処置または予防するための方法
US8067432B2 (en) 2008-03-31 2011-11-29 University Of Kentucky Research Foundation Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors
CN102057054B (zh) 2008-04-11 2015-06-10 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
JP5677972B2 (ja) 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
JP2012525371A (ja) * 2009-05-01 2012-10-22 オンコザイム・ファーマ・インコーポレイテッド 癌を治療するためのペンタミジンの組み合わせ
RU2526114C2 (ru) 2009-12-03 2014-08-20 Цзянсу Хэнжуй Медицин Ко., Лтд. Липосомы иринотекана или его солей, способ их получения
US9399071B2 (en) 2010-06-04 2016-07-26 Abraxis Bioscience, Llc Methods of treatment of pancreatic cancer
WO2012012454A1 (en) 2010-07-19 2012-01-26 Bipar Sciences, Inc. Methods of treating metastatic breast cancer with 4-iodo-3-nitrobenzamide and irinotecan
EP2595657A4 (en) 2010-07-22 2015-09-23 Univ California ANTITUMOR ANTIBODY ANTIBODIES AND METHODS OF USING SAME
WO2012031293A1 (en) 2010-09-03 2012-03-08 Board Of Regents Of The University Of Nebraska Compositions and methods for the treatment of cancer
JP6208582B2 (ja) 2010-12-06 2017-10-04 メリマック ファーマシューティカルズ インコーポレーティッド アントラサイクリン系化学療法剤を含有しているｅｒｂｂ２標的免疫リポソームによる治療における心臓毒性を抑制するための用量及び投与
JP5947807B2 (ja) 2010-12-14 2016-07-06 テクニカル ユニバーシティ オブ デンマークＴｅｃｈｎｉｃａｌ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｄｅｎｍａｒｋ ナノ粒子組成物への放射性核種の封入
CA2827118A1 (en) 2011-02-15 2012-08-23 Merrimack Pharmaceuticals, Inc. Compositions and methods for delivering nucleic acid to a cell
SI2699602T1 (sl) 2011-04-19 2017-06-30 Merrimack Pharmaceuticals, Inc. Bispecifična protitelesa anti-igf-1r in anti-erbb3
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
AU2013201584A1 (en) 2012-03-12 2013-09-26 Merrimack Pharmaceuticals, Inc. Methods for treating pancreatic cancer using combination therapies comprising an anti-ErbB3 antibody
US9511155B2 (en) 2012-04-17 2016-12-06 Merrimack Pharmaceuticals, Inc. Compositions and methods for non-invasive imaging
AU2013202947B2 (en) * 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013374248A1 (en) 2012-12-14 2015-06-11 Merrimack Pharmaceuticals, Inc. Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic agents
KR101848131B1 (ko) 2013-03-27 2018-04-11 다이호야쿠힌고교 가부시키가이샤 저용량 이리노테칸염산염 수화물을 함유하는 항종양제
US10111871B2 (en) 2013-08-27 2018-10-30 Northeastern University Nanoparticle drug delivery system and method of treating cancer and neurotrauma
WO2015061592A1 (en) 2013-10-23 2015-04-30 Merrimack Pharmaceuticals, Inc. Liposomes for non-invasive imaging and drug delivery
EP3229802A1 (en) * 2014-12-09 2017-10-18 Ipsen Biopharm Ltd. Treatment of breast cancer with liposomal irinotecan
WO2016168451A1 (en) 2015-04-14 2016-10-20 Merrimack Pharmaceuticals, Inc. Compositions for improving the pharmacokinetics and therapeutic index of cancer treatment
CA2992789A1 (en) 2015-08-20 2017-02-23 Ipsen Biopharm Ltd. Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
EP3791876A1 (en) 2015-08-21 2021-03-17 Ipsen Biopharm Ltd. Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
MX2018004328A (es) 2015-10-16 2018-08-01 Ipsen Biopharm Ltd Composiciones farmaceuticas estabilizantes de camptotecina.
US20170202840A1 (en) 2016-01-14 2017-07-20 Merrimack Pharmaceuticals, Inc. Treatment of pancreatic cancer with liposomal irinotecan
WO2017172678A1 (en) 2016-03-30 2017-10-05 Merrimack Pharmaceuticals, Inc. Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan
US20170333421A1 (en) 2016-05-18 2017-11-23 Ipsen Biopharm Ltd. Population Pharmacokinetics of Liposomal Irinotecan
CN109640995A (zh) 2016-05-18 2019-04-16 易普森生物制药有限公司 用脂质体伊立替康治疗小细胞肺癌
CN106420789A (zh) * 2016-10-08 2017-02-22 中国人民解放军总医院 复发耐药消化道肿瘤地西他滨综合治疗方案
SG11201903615WA (en) 2016-11-02 2019-05-30 Ipsen Biopharm Ltd Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)

Also Published As

Publication number Publication date
AU2016310476B8 (en) 2021-10-07
TWI778942B (zh) 2022-10-01
CA2993451A1 (en) 2017-03-02
CN108495629A (zh) 2018-09-04
TW201717933A (zh) 2017-06-01
BR112018002941B1 (pt) 2023-12-05
EP3337478B1 (en) 2020-08-12
HK1257250A1 (zh) 2019-10-18
US11344552B2 (en) 2022-05-31
EP3337478A1 (en) 2018-06-27
ES2826826T3 (es) 2021-05-19
RU2747124C2 (ru) 2021-04-28
AU2016310476A1 (en) 2018-02-22
JP2022009657A (ja) 2022-01-14
US20180078556A1 (en) 2018-03-22
US20170049775A1 (en) 2017-02-23
RU2018105666A (ru) 2019-09-23
EP3791876A1 (en) 2021-03-17
JP2024045587A (ja) 2024-04-02
SI3337478T1 (sl) 2020-10-30
AU2016310476B2 (en) 2021-09-30
KR20180039087A (ko) 2018-04-17
SG10201913077QA (en) 2020-02-27
TW202126293A (zh) 2021-07-16
RU2018105666A3 (pt) 2020-02-21
BR112018002941A2 (pt) 2018-11-27
IL257149A (en) 2018-03-29
MX2018001802A (es) 2018-05-16
WO2017034957A1 (en) 2017-03-02
TW202400181A (zh) 2024-01-01
TW202243677A (zh) 2022-11-16
JP2018528185A (ja) 2018-09-27
US20230062425A1 (en) 2023-03-02
JP7463329B2 (ja) 2024-04-08
HK1257220A1 (zh) 2019-10-18

Similar Documents

Publication Publication Date Title
HK1257250A1 (zh) 使用包括脂質體伊立替康和奧沙利鉑的組合療法治療轉移性胰腺癌的方法
ZA201701491B (en) Methods and therapeutic combinations for treating tumors
IL255780A (en) Therapeutic combinations and methods for treating neoplasia
IL291679A (en) Gastric cancer treatment using combined treatments containing liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin)
IL304820A (en) Preparations and methods for the treatment of cancer
IL253573A0 (en) Combined therapies for the treatment of cancers
HK1209627A1 (en) Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
SG11201700079VA (en) Combination therapy compositions and methods for treating cancers
PT3377516T (pt) Composição para o tratamento do cancro
HK1259342A1 (zh) 用於治療癌症的聯合療法
IL256523A (en) Compositions and methods for treating cancer
IL262656A (en) Nanoliposomal irinotecan for use in the treatment of small cell lung cancer
HK1255939A1 (zh) 用於治療癌症之組合療法
IL255638A (en) Compositions and methods for treating cancer
EP3468564A4 (en) METHOD FOR DIAGNOSTICING AND TREATING METASTASIVE CANCER
IL270820A (en) Antisense therapies for cancer treatment
EP3303289A4 (en) Compounds and methods for treating cancer
PT3265106T (pt) Novo método para tratamento e prognóstico do cancro
ZA201802268B (en) Methods and compositions for preventing or treating cancer
ZA201900438B (en) Combination therapies for treating cancer
PT2892560T (pt) Métodos e produtos para prevenção e/ou tratamento do cancro metastático
HK1250958A1 (zh) 用於治療癌症的組合物和方法
GB201720089D0 (en) Means and methods for treating cancer
GB201609402D0 (en) Materials and methods for treating cancer